Finance

Mga Listahan
NOT:FRA
Novartis AG
€124.58
-0.80%
(-1.00) 1D
Okt 2, 10:00:00 PM GMT+2  ·   EUR
Lahat ng simbolo
SimboloPresyoPalitan% ng Pagbabago
Bumubuo ng mga nangungunang insight para sa NOT...
Buksan
€125.78
Mataas
€127.10
Mababa
€124.46
Mkt. cap
289.09B
Avg. na dami
1.04K
Dami
1.04K
Mataas nang 52-wk
€144.08
Mababa nang 52-wk
€105.36
Bilang ng mga empleyado
75K
Buksan
€125.78
Mataas
€127.10
Mababa
€124.46
Mkt. cap
289.09B
Avg. na dami
1.04K
Dami
1.04K
Mataas nang 52-wk
€144.08
Mababa nang 52-wk
€105.36
Bilang ng mga empleyado
75K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Tungkol sa Novartis AG
CEOVasant Narasimhan
Mga Empleyado75.3K
ItinatagMar 7, 1996
HeadquartersBasel, Basel City, Switzerland
Sektor-
Mga nakaraang ulatLahat ng value sa USD
Loading Previous Earnings...
Kita
Net na kita
Lahat ng value sa USD
Set 2025
Dis 2025
Mar 2026
Hun 2026
Kita
14.36B
13.86B
13.52B
14.95B
Gastusin sa mga naibentang produkto
3.54B
3.54B
3.44B
3.68B
Halaga ng kita
3.54B
3.54B
3.44B
3.68B
Mga gastos sa pananaliksik at pag-develop
2.86B
2.84B
2.78B
2.74B
Kabuuang gastos sa pananaliksik at pag-develop
-
-
-
-
Mga gastos sa pagbebenta, pangkalahatan, at admin
3.30B
3.44B
3.14B
3.23B
Gastos sa pagpapatakbo
6.24B
6.46B
5.96B
6.10B
Kabuuang gastos sa pagpapatakbo
9.77B
10.00B
9.40B
9.78B
Kita sa pagpapatakbo
4.58B
3.86B
4.12B
5.18B
Iba pang hindi kita sa pagpapatakbo
-7.00M
-130.00M
4.00M
19.00M
EBT na may mga hindi karaniwang item
4.20B
3.22B
3.84B
4.27B
EBT na hindi kasama ang mga hindi karaniwang item
4.29B
3.49B
3.78B
4.73B
Gastos sa buwis sa kita
266.00M
814.00M
683.00M
1.01B
Epektibong rate ng buwis
6.34%
25.30%
17.79%
23.71%
Iba pang gastos sa pagpapatakbo
70.00M
190.00M
42.00M
127.00M
Net na kita
3.93B
2.41B
3.16B
3.26B
Margin ng kabuuang kita
27.36%
17.38%
23.34%
21.83%
Kita bawat share
2.25
2.03
1.99
2.41
Kita sa interes at investment
-
373.00M
-
-
Gastos sa interes
-281.00M
-304.00M
-343.00M
-462.00M
Mga net na gastos sa interes
-281.00M
69.00M
-343.00M
-462.00M
Mga singil sa depreciation at amortization
-
-
-
-
EBITDA
5.78B
4.96B
5.24B
6.30B
Kita o pagkalugi mula sa pagbebenta ng mga asset
81.00M
80.00M
-159.00M
-247.00M
Posibleng magkaroon ng mga pagkakamali ang AI content. Matuto pa
Mga app ng Google